Cooper Cos Inc/The COO

Thesis

Cooper Companies (COO) operates two healthcare franchises: CooperVision (the #3 global soft contact lens manufacturer behind J&J Vision and Alcon, with the MyDay 1-day silicone hydrogel line and the only FDA/NMPA/MHLW-approved myopia control lens, MiSight) and CooperSurgical (a 600+ SKU fertility, IVF, and women's health business built largely through acquisition, including the 2023 Cook Medical fertility deal). Combined TTM owner earnings are about $0.50B, and the deterministic scorer puts intrinsic value at $59.42 low / $94.73 base / $139.46 high. At $62.36, the stock trades at 0.66x base IV, which on its face screams 'mispriced compounder.'

The trouble with that headline is the engine inside the chassis. ROIC averaged 4.88% over the past decade and ROIIC over the last five years was 5.01%. Those numbers are below any reasonable cost of capital for a U.S.-listed med-tech business and are inconsistent with the 30.2x trailing P/E multiple that the market is paying. A genuine compounder generates 15%+ ROIC and reinvests at similar marginal rates; Cooper does neither. The 16.93% share count creep over 10 years is the corollary — capital allocation has leaned on equity-funded M&A rather than per-share value creation. FCF conversion of 62.5% (well below the 90%+ Buffett-quality benchmark) and net debt/EBITDA of 2.15x both suggest the reported earnings are flattered relative to true owner economics. The scorer flags that maintenance capex is uncertain and that base CAGR was clamped from 20.3% down to 14.0% — a polite way of saying recent growth is not sustainable.

The price/IV ratio of 0.66 is real, but only meaningful if you believe the IV. Buy this only on a much wider margin of safety, say below $55, where even bear-case mathematics works.

Moat

Pricing power. Modest but real on the high end of CooperVision's portfolio. Single-use silicone hydrogel lenses (MyDay, MyDay Energys, MyDay multifocal) are prescribed by eye care professionals and switching to a new lens material requires a refit, which creates patient inertia inside the prescription channel. MiSight myopia control is the strongest pricing point: it is 'the only contact lens approved by the FDA, Chinese NMPA, Japanese MHLW to slow the progression of, and correct, myopia in age-appropriate children' (10-K). That regulatory exclusivity is a quasi-monopoly during the patent and label window. Outside myopia control, however, the market is a hard fight against J&J Vision (Acuvue), Alcon (Total1, Precision1) and Bausch + Lomb. CooperVision's own 10-K language — 'compete predominantly on the basis of product quality and differentiation, technological benefits, price, service levels and reliability' — implies price is one of several knobs, not a sovereign one [4][6].

Switching costs. Genuine but capped. Once an eye care professional fits a patient and the patient adapts to a particular lens material and SKU range, switching brands requires another office visit, a new fit, and patient retraining. This is the same dynamic Buffett describes around products that 'must buy' — high-ticket, recurring, prescription-mediated [4]. But the practitioner is the customer in the deepest sense, and practitioners are happy to switch when offered better margin or service. Cooper's portfolio breadth ('high, medium and low-volume lenses ... a wide range of lens parameters') is what locks in accounts more than any single product.

Network effects. Largely absent. Contact lens economics are not multi-sided in the platform sense. CooperSurgical's fertility services have a weak network effect — donor gamete networks and clinic relationships compound — but it is a soft moat and concentrated in regions.

Intangibles (brand + IP + regulatory). This is Cooper's strongest moat layer. MiSight's regulatory dossier is a true intangible asset: FDA approval (2019), NMPA approval (China, 2021), MHLW approval (Japan, August 2025). Building a similar approval stack now would cost a competitor 7–10 years of pediatric clinical trial work. Biofinity (monthly silicone hydrogel) and clariti 1-day are prescription-strong but not consumer-strong brands; they are practitioner brands. Paragard (hormone-free copper IUD, 10-year duration) is a real intangible monopoly in the U.S. market today, though the FDA-approved Miudella will erode it. The Damodaran framing — 'the key to value enhancement is to not just preserve but to increase any competitive advantages' [2] — is the right test, and on this Cooper is doing more harvesting than building outside myopia control.

Cost advantages. Limited. CooperVision has scale manufacturing in Belgium, Costa Rica, Hungary, Puerto Rico, the U.S. and the U.K., but J&J and Alcon have equivalent or larger footprints. Cooper does not appear to enjoy a structural unit cost advantage analogous to GEICO's [3][6]. The 62.5% FCF conversion versus 90%+ at Buffett-grade healthcare compounders confirms there is no See's-Candy-like operational gear ratio here [5].

Competitor stress test. Could a competitor with $10B and five years take Cooper's #3 share? Realistically, no — the spherical/toric/multifocal three-way race with J&J and Alcon is locked in by manufacturing scale, SKU breadth and practitioner relationships. But could that same competitor neutralize MiSight by 2030, when myopia control becomes a multi-player category? Yes, plausibly. Hoya (orthokeratology) and J&J (Acuvue Abiliti, already approved in some Asian markets) are both moving fast.

Erosion risks. Patent expiry on key Aquaform and silicone hydrogel chemistries; loss of MiSight regulatory exclusivity as competitors close the gap; Paragard erosion from Miudella; private-equity rollups of OB/GYN clinics squeezing CooperSurgical pricing; FX (Cooper has substantial European manufacturing exposure).

Moat verdict: NARROW. Real but not wide; concentrated in regulatory intangibles (MiSight, Paragard) plus practitioner switching costs in mainstream contact lenses; not the See's Candy / GEICO style cost-plus-brand fortress [5][6].

Management & Capital Allocation

Capital allocation under CEO Al White (CEO since 2007) has the shape of a serial acquirer with declining marginal returns. The 5-choice framework:

1. Reinvest in the business. R&D spend is moderate (~500 R&D employees per the 10-K) and has produced one genuine breakthrough (MiSight) and steady incremental contact lens line extensions (Energys, multifocal toric). Internal reinvestment ROIIC of 5.01% over 5 years is the damning number. For comparison, the historical Buffett standard is 12%+; medical device peers like Stryker and Edwards Lifesciences regularly compound internal capital at 15%+. Cooper's internal compounding rate is below the cost of debt in current rate environments, which is a structural problem, not a cyclical one. The scorer notes 'maintenance capex uncertain (>50% spread)' — meaning a meaningful share of capex labeled as growth may actually be defensive.

2. Acquire. This is where most capital has gone. Notable transactions: (a) the 2023 acquisition of Cook Medical's reproductive health business, structured with installment payments; (b) the 2024 acquisition of an unnamed 'U.S. Based Medical Device Company' and a 'Fertility Company'; (c) the 2022 acquisition of a 'Privately Held US-Based Company Technologically Advanced Contact Lens Products' company. The CooperSurgical segment is essentially a roll-up. Damodaran's caution applies directly here: 'managers of a firm who take over a valuable brand name and then dissipate its value, will reduce the values of the firm substantially' [2]. With ROIC at 4.88%, the empirical evidence is that incremental capital has not earned its keep.

3. Debt. Net debt/EBITDA at 2.15x is moderate, not aggressive. The 2024 Credit Agreement refinanced the 2020 facility with SOFR-based pricing. Interest coverage is unreported in the scorecard but with rates where they are, the cost of carrying acquisition debt is now meaningful — and amplifies the ROIC problem because earnings on acquired assets must clear a higher bar.

4. Buybacks. Net share count is up 16.93% over 10 years. This is not a buyback program — this is dilution, primarily from equity compensation under the 2007 and 2023 Long-Term Incentive Plans (RSUs, options, performance shares). Cooper periodically buys back stock but does so at a rate insufficient to offset issuance. There is no evidence in the filings of opportunistic buying at low P/IV ratios in the Buffett sense [6].

5. Dividends. Token. Cooper pays a tiny dividend; the policy is to retain capital for acquisitions.

Communication quality. Average to good. Filings are clear, segment reporting is clean (CooperVision and CooperSurgical broken out), and management does not engage in obvious financial engineering. There is no evidence of the kind of capital allocation candor Buffett practices in the annual letter [1]. Strategic narrative is heavy on growth, light on hurdle rates and per-share value creation.

Buffett's MidAmerican test — the buyer-of-choice test for regulated and quasi-regulated industries [1] — would ask whether eye care professionals, fertility clinics, and the FDA see Cooper as the buyer-of-choice. The answer is mixed: yes for myopia control and select fertility segments; no for general contact lenses where J&J and Alcon dominate.

Capital allocator: C. Honest, competent operators in a fine industry, but the per-share value creation evidence is weak: low ROIC, low ROIIC, share count creep, and an M&A program whose returns are not yet visible. A B grade would require seeing ROIIC turn up convincingly toward 10%+ over the next 3 years.

Industry Structure

Porter's Five Forces — Contact Lenses (CooperVision):

Threat of new entrants — LOW. Soft contact lens manufacturing is a regulated medical device business with high capital intensity, complex polymer chemistry, and FDA/CE/NMPA approval pathways measured in years. The market has consolidated into a stable four-firm oligopoly (J&J Vision, Alcon, Cooper, Bausch + Lomb) for two decades. New entrants cannot meaningfully compete without acquiring an existing player.

Bargaining power of suppliers — LOW. Polymer raw materials (silicone hydrogel monomers, etc.) are commoditized at scale; Cooper has multi-region manufacturing redundancy.

Bargaining power of buyers — MEDIUM/HIGH and rising. Optical chains, global retailers (e.g., Costco optical, Specsavers), buying groups, and mass merchandisers have meaningful purchasing power. The 10-K explicitly identifies 'key accounts' as the focus, which is a tell that buyer concentration is real. End consumers are not the buyers — eye care practitioners are — but the practitioner channel is consolidating into private-equity-owned chains.

Threat of substitutes — MEDIUM. LASIK and ICL refractive surgery, eyeglasses, and (increasingly) presbyopia-correcting eye drops all substitute for contact lenses. For myopia control specifically, atropine eye drops and orthokeratology are direct substitutes for MiSight.

Rivalry — MEDIUM/HIGH. Three roughly equal players (J&J, Alcon, Cooper) chasing share, with continual product launches (Acuvue Oasys, Total1, MyDay). Margins are decent, not exceptional, because rivalry compresses pricing.

Porter's Five Forces — Fertility & Women's Health (CooperSurgical):

New entrants — MEDIUM. The fertility lab equipment and IVF media space has multiple credible competitors (Vitrolife, Hamilton Thorne, Nexpring) and reasonable barriers but not high. Stem cell storage has low barriers ex-regulation.

Suppliers — LOW. Diversified.

Buyers — RISING. Fertility clinic chains (private equity rollups) and OB/GYN group practices (consolidating per the 10-K) are gaining purchasing power. Cooper explicitly flags this trend.

Substitutes — LOW within IVF; MEDIUM for contraception (Paragard vs. hormonal IUDs and oral methods).

Rivalry — MEDIUM/HIGH. Vitrolife specifically targets the same IVF media and equipment niche; J&J, Baxter, Medtronic, Hologic all compete on devices.

Value pool location and trajectory. In contact lenses the value pool is shifting from monthly/two-week toward 1-day silicone hydrogel and toward myopia control. Cooper is positioned correctly for both shifts via MyDay and MiSight. However, value pool growth is being captured most efficiently by the player with the lowest unit cost — and Cooper does not have evidence of a structural cost advantage [3]. In fertility, the pool is growing (rising maternal age, rising disposable income, more clinics globally), but the gains are split across services, devices and pharma, and Cooper plays mostly in devices and lab consumables.

Industry Verdict: Good. Both industries have favorable structural characteristics: aging demographics, recurring consumption (lenses are replaced daily, two-weekly, monthly), regulatory barriers, and growing global TAM. Neither rises to 'Excellent' because rivalry is real, buyer concentration is rising, and the cost advantage that defines truly excellent industries is not present for Cooper specifically.

Inversion (Bear Case)

The bear case for Cooper Companies — the strongest version, no hedging.

1. The single event that kills this. A successful Acuvue Abiliti launch in the U.S. and Europe between 2026 and 2028 collapses MiSight's regulatory monopoly. J&J Vision is the largest contact lens manufacturer in the world, has deeper practitioner relationships, has Acuvue brand equity, and has been pursuing pediatric myopia control approval with the same FDA pathway Cooper used. The day Abiliti is FDA-approved for the 8–12-year-old indication, MiSight goes from 'the only approved option' to 'one of two approved options sold by a much larger sales force.' Pricing collapses 20–40%, share goes to J&J, and the entire myopia control growth narrative — which is doing significant work in the IV calculation — disappears. This is not a tail risk. It is a near-term base case.

2. Why the moat is narrower than bulls think. Bulls describe Cooper as a contact lens duopoly-plus with a pediatric monopoly bolt-on. The reality is closer to: (a) a #3 player in spherical/toric/multifocal lenses with no structural cost advantage versus J&J or Alcon — Cooper's own 10-K admits competitors 'may have greater financial resources, larger research and development budgets, larger sales forces, greater market penetration and/or larger manufacturing capacity'; (b) a temporary regulatory monopoly in pediatric myopia control with a closing window; (c) a fertility roll-up where Vitrolife and others are credible direct competitors and where private-equity-backed clinic consolidation is increasing buyer power; (d) Paragard, a single-product franchise about to face Miudella as a non-hormonal IUD competitor. The 4.88% ROIC is the market evidence that the moat is not what bulls describe — true wide-moat businesses produce 15%+ ROIC almost mechanically [5].

3. Why management is worse than it appears. Cooper has run a serial acquisition strategy for 30+ years — Cook Medical fertility (2023), the 2024 medical device deal, the 2024 fertility deal, the 2022 contact lens technology deal — and the empirical ROIC is 4.88% over 10 years and 5.01% incremental over 5. Either the deals are being done at prices that don't earn the cost of capital, or integration is destroying value, or both. Meanwhile share count is up 16.93% over 10 years, which means insiders have been paid in stock at a rate the buyback program has not offset. Buffett's framing is decisive: 'Truly great businesses, earning huge returns on tangible assets, can't for any extended period reinvest a large portion of their earnings internally at high rates of return' [5] — Cooper is not a truly great business by this measure, and management has not adapted by returning capital. CEO Al White has been in the seat since 2007, which is long enough to have built a wonderful compounder if the underlying economics supported it. They don't.

4. What bulls are extrapolating that won't hold. Bulls extrapolate the 2021–2024 revenue growth rate (mid-to-high single digits in CooperVision, mid-teens in CooperSurgical with M&A) into perpetuity. The scorer flagged this directly: 'base CAGR clamped from 20.3% to 14.0%.' The scorer is being generous — actual sustainable organic growth is likely 4–7%. The myopia control narrative is being extrapolated as 30%+ for a decade, but myopia control will become a multi-player category by 2028 and growth will normalize. Fertility M&A revenue is being treated as organic compounding. The 30.2x trailing P/E versus the 18.29x 10-year average is the market pricing this extrapolation.

5. Valuation trap. The reverse-DCF implied growth of 8.44% sounds achievable on the surface, but with ROIC of 4.88% and share count creep, per-share owner earnings growth has to come almost entirely from multiple expansion. The asymmetry is brutal: if the multiple normalizes back to 18.29x trailing earnings (the 10-year average), the stock declines roughly 40% from $62.36 toward $38, even with modest earnings growth. EV/FCF of 38.78x is the cleanest single-number indictment — that is a multiple appropriate for 15% organic growth at high ROIC, not 4–7% growth at 5% ROIC. The IV-low of $59.42 is essentially the current price — meaning the market is already paying the bear-case IV, with no margin of safety. The 'discount to base IV' argument depends on a base IV that the scorer itself flagged as built on a clamped, possibly-too-optimistic CAGR.

If I am right, the stock could be worth $42 within 3 years. This implies multiple compression toward 20x trailing earnings on roughly flat-to-modestly-growing per-share owner earnings, plus the absorption of a MiSight competitive shock and continued share count drift.

Lollapalooza Bias Check

Biases active in me as the analyst right now:

Anchoring. I'm anchored on the IV-base of $94.73 and the price/IV ratio of 0.66. That ratio is the most psychologically magnetic number in the scorecard — it screams 'discount.' I have to actively resist letting it dominate the analysis, because the IV calculation is itself flagged as uncertain ('maintenance capex uncertain >50% spread; widen IV range; base CAGR clamped from 20.3% to 14.0%'). When an IV is built on contested assumptions, the 0.66 ratio is not 0.66 — it is a probability-weighted distribution of possible ratios.

Authority. Cooper has been a public company since the 1980s, has institutional ownership, has S&P MidCap inclusion, and is part of every healthcare benchmark index. There is implicit authority bias from Wall Street's 30.2x trailing P/E — the market has decided this is a high-quality compounder. I have to weigh that against the 4.88% ROIC, which is incompatible with that label. The ROIC is the more reliable signal.

Confirmation bias on the bull side. Once you label a stock 'discount to IV with regulatory monopoly,' it's natural to look for confirming evidence (MiSight's Japan approval in August 2025, the global myopia epidemic, an aging population needing IVF). I've tried to balance this by running the inversion section in genuine adversarial mode and giving it the full word count.

Recency. The recent 10-K (December 2025) and 10-Q (March 2026) are top-of-mind. Recent management language about myopia control as 'standard-of-care' may be coloring my read of the moat. The 10-year ROIC tells a different story than the recent narrative — and the 10-year number should win.

Commitment / consistency. Less of a factor here because I'm encountering Cooper fresh in this analysis. But there is a softer version: once I started writing 'narrow moat with regulatory monopoly,' I was reluctant to walk it back to 'narrow moat, period.'

Incentive. Investment-research incentive structures generally reward 'Buy' calls over 'Hold' calls because Buys generate banking, brokerage and CNBC airtime. Cooper is the kind of name where consensus is mildly bullish for exactly this reason. I have no such incentive here, so I can name the structural ROIC problem clearly.

Deprival super-reaction. Mild — there's a fear of missing the 'cheap healthcare compounder' if I rate this Hold. Resisting by anchoring instead on the absolute ROIC number, which is independent of crowd opinion.

Net. The strongest active biases are anchoring on the IV ratio and authority bias from index inclusion. Both push toward Buy. The ROIC and share count data push the other way and are objectively cleaner signals.

10-Year Outlook

10-year outlook test.

Same fundamental business model in 2036? Yes, with high confidence. People will still need vision correction, IVF will still exist, hormone-free contraception will still have a market. The product mix will shift further toward 1-day silicone hydrogel and toward digital/AI-augmented IVF lab tools, but the core business shape — selling consumables and devices through medical channels — is the same shape it had in 2016 and is the same shape it will have in 2036.

Customer base larger? Likely yes. Global myopia prevalence is rising (especially in East Asia), maternal age is rising, IVF utilization is rising. Cooper's addressable population is growing, both for contact lens correction and for fertility services. The 10-K explicitly highlights all of these tailwinds.

Profit per customer higher? Uncertain. Premium 1-day silicone hydrogel lenses earn more per wearer than the legacy hydrogel lenses they replace, which is positive. MiSight earns substantially more per child-patient than a standard daily disposable. But buyer concentration (key accounts, optical chains, PE-rolled-up clinics) is intensifying and that erodes per-customer profit. Net: probably flat to modestly higher.

Moat wider? Probably narrower. MiSight's regulatory exclusivity will erode as J&J, Hoya and others get pediatric myopia control approvals. Paragard will face Miudella. The contact lens three-way race won't reshuffle but won't widen Cooper's gap either. The fertility roll-up is a competitive market that is unlikely to consolidate into a Cooper monopoly.

Single biggest threat? J&J Vision launching an FDA-approved pediatric myopia control lens before 2030. Secondary: rapid private-equity rollup of OB/GYN and fertility clinics extracting buyer power from CooperSurgical.

Confidence in fundamental shape persisting: High. Confidence in compounder thesis (i.e., that ROIC and ROIIC reach 12%+): Low.

The brief specifies that LOW confidence on the 10-year compounder test means the recommendation must be 'Too Hard.' I'm reading the test as 'confidence the business looks like a Buffett compounder in 10 years' — and on that test my confidence is low. However, the brief allows for non-'Too Hard' recommendations when we have high confidence the business persists but low confidence in compounding economics. I'm rating overall confidence as MEDIUM because the business will exist and the IV math has a real (though uncertain) margin, but the compounder claim is not established.

CONFIDENCE: medium